EI
FPRX

EAM Investors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

EAM Investors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-134,162
Closed -$2.28M – 484
2020
Q4 		$2.28M Buy
+134,162
New +$1.68M 0.37% 79
2017
Q1 		– Sell
-10,480
Closed -$525K – 397
2016
Q4 		$525K Sell
10,480
-5,239
-33% -$275K 0.07% 299
2016
Q3 		$825K Sell
15,719
-5,200
-25% -$248K 0.11% 272
2016
Q2 		$865K Sell
20,919
-8,654
-29% -$376K 0.13% 272
2016
Q1 		$1.2M Sell
29,573
-7,741
-21% -$266K 0.19% 207
2015
Q4 		$1.55M Buy
+37,314
New +$1.25M 0.2% 199
2015
Q2 		– Sell
-44,488
Closed -$1.02M – 400
2015
Q1 		$1.02M Buy
+44,488
New +$1.12M 0.12% 299

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

EAM Investors's FPRX Position: Q1 2021 in Review

EAM Investors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 134,162 shares — an estimated $2.28M sold.

EAM Investors first reported a position in FPRX in Q1 2015 and held it in 7 quarters. The position peaked at $2.28M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • EAM Investors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 134,162 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $2.28M.
  • EAM Investors first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 7 quarters.
  • EAM Investors's Five Prime Therapeutics, Inc. position peaked at $2.28M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.